TABLE 1

Patients’ Characteristics Stratified by Initial Therapy Received

Baseline CharacteristicsIVIg Only, n = 33IVIg and Infliximab, n = 58IVIg and Corticosteroids, n = 30Pa
Age in y, median (IQR)2.0 (1.2 to 5.6)1.1 (0.5 to 3.0)2.6 (0.9 to 4.5).04
Infant <6 mo, n (%)9 (27)16 (28)5 (17).29
Boy, n (%)19 (58)44 (77)25 (83)<.001
Length of fever in d, median (IQR)6 (4 to 7)5 (3 to 6)6 (4 to 7).28
Complete clinical criteria, n (%)20 (61)46 (79)11 (37)<.001
Persistence of fever after IVIg treatment, n (%)7 (21)8 (14)0 (0).02
Additional therapies, n (%)14 (42)19 (33)17 (57).10
Second dose of IVIgb, n (%)11 (33)10 (17)17 (57).001
Other immunosuppressive therapies, n (%)11 (33)12 (21)3 (10).084
  • a Nonparametric test for median for continuous values; Fisher exact test for qualitative values.

  • b A second dose of IVIg was routinely administered in patients with CAAs at the center using corticosteroids, irrespective of clinical response to first IVIg treatment.